DDetect liver cancerDetectCancer.org

Cirrhosis surveillance, ultrasound, AFP and multiphase imaging

Liver cancer is one of the cancers where surveillance is clearly risk-based.

For cirrhosis and selected hepatitis B groups, surveillance with ultrasound, often with AFP, can find hepatocellular carcinoma earlier. Average-risk screening is not routine.

Screening realitySymptoms not to ignoreImmunotherapyVaccines
Educational, not personal medical advice. Jaundice, ascites, right upper abdominal pain, weight loss, a new liver lesion, rising AFP or decompensating cirrhosis needs prompt assessment. Liver cancer and bile duct cancer can overlap in symptoms but are different diseases.
6 months

is the common ultrasound surveillance interval in many HCC programs.

AFP

can help but is not reliable alone.

CT/MRI

multiphase arterial enhancement and washout often establish HCC diagnosis.

Risk-based

cirrhosis, hepatitis B/C and other liver disease define who benefits.

Brief outline

Primary liver cancer is usually HCC or cholangiocarcinoma.

Hepatocellular carcinoma arises from liver cells, often in cirrhosis or chronic hepatitis. Cholangiocarcinoma arises from bile ducts and has different risk factors, imaging and markers.

Liver cancer cross-sectional imaging.
Multiphase CT/MRI is central to liver cancer diagnosis.

Detection frame

Liver cancer detection is one of the clearest examples of targeted surveillance: test people with enough risk for the signal to be useful, not everyone with a normal liver.

Do not ignore

Symptoms often mean more advanced disease.

JaundiceYellow eyes/skin, dark urine, pale stools and itching can occur with liver failure or bile duct obstruction.
Right upper quadrant painPersistent pain, fullness or shoulder-tip discomfort needs context.
Weight loss or appetite lossUnexplained weight loss in chronic liver disease is a warning.
Ascites or swellingNew abdominal fluid or leg swelling can mean decompensation or cancer progression.
GI bleeding or confusionCirrhosis complications require urgent care and may coexist with HCC.
New liver lesionA lesion in a cirrhotic liver deserves liver-protocol CT/MRI, not casual follow-up.

Risk and genetics

Cirrhosis and viral hepatitis drive surveillance.

CirrhosisFrom hepatitis C, hepatitis B, alcohol, NASH/MASLD, autoimmune or other causes.
Hepatitis BCan cause HCC even without cirrhosis in some groups; risk depends on age, ancestry, family history and viral factors.
Hepatitis CRisk drops after cure but may persist if cirrhosis is present.
Metabolic liver diseaseDiabetes, obesity and fatty liver disease are increasingly important.
Aflatoxin and alcoholGlobal and lifestyle exposures add risk.
Cholangiocarcinoma risksPSC, liver flukes, choledochal cysts and biliary disease can matter.

Screening

Surveillance is for high-risk liver disease, not average-risk adults.

Many liver societies recommend ultrasound every 6 months, often with AFP, for cirrhosis and selected hepatitis B groups. Ultrasound quality can be poor in obesity or nodular cirrhosis; CT/MRI alternatives are sometimes considered.

Surveillance

Ultrasound +/- AFP

Usually every 6 months in eligible high-risk people.

Marker

AFP

Helpful when rising but not sensitive or specific enough alone.

Diagnostic

Multiphase CT

Assesses arterial enhancement, washout, vascular invasion and metastases.

Diagnostic

MRI liver protocol

Often more sensitive for small lesions; useful when ultrasound is limited.

Selective

Biopsy

Used for indeterminate imaging, non-cirrhotic liver, suspected cholangiocarcinoma or metastasis.

Caution

Whole-body MRI

May find liver lesions but cannot replace structured HCC surveillance in known cirrhosis.

Images, labs and tissue

HCC may be diagnosed by imaging pattern, not always biopsy.

In high-risk patients, arterial phase hyperenhancement with portal/delayed washout on multiphase CT or MRI can diagnose HCC. Biopsy is used when imaging is indeterminate or the patient is not in a classic risk group.

Liver cancer cross-sectional imaging.
Multiphase CT/MRI is central to liver cancer diagnosis.
CT image of liver metastases/lesions.
Not every liver lesion is HCC; context matters.
Liver function blood tests.
Blood tests help triage but cannot screen alone.

Pros, cons and controversy

The controversy is not whether HCC surveillance matters, but whether it is done well.

Ultrasound can miss early HCC, especially with obesity or nodular cirrhosis. AFP creates false positives. But unlike many cancers, there is a clear high-risk group where repeated surveillance can shift stage and open transplant/ablation/resection options.

Liver detection trials ImmunotherapyForLiverCancer.com VaccineForLiverCancer.com TheCancers.com

Sources and trials

Good starting points.

NCI liver cancerLiver cancer overview and diagnostic context. AASLD HCC guidanceHCC surveillance and diagnosis guidance. ClinicalTrials.gov liver detectionDetection and surveillance trials.